Choreo LLC Makes New Investment in Catalent, Inc. (NYSE:CTLT)

Choreo LLC acquired a new stake in shares of Catalent, Inc. (NYSE:CTLT - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 24,360 shares of the company's stock, valued at approximately $1,094,000.

Several other institutional investors also recently made changes to their positions in CTLT. Headlands Technologies LLC acquired a new position in shares of Catalent during the 4th quarter valued at $64,000. Tokio Marine Asset Management Co. Ltd. lifted its holdings in shares of Catalent by 6.2% during the 4th quarter. Tokio Marine Asset Management Co. Ltd. now owns 5,703 shares of the company's stock valued at $256,000 after acquiring an additional 331 shares in the last quarter. GAMMA Investing LLC acquired a new position in shares of Catalent during the 4th quarter valued at $33,000. North Star Asset Management Inc. lifted its holdings in shares of Catalent by 16.8% during the 4th quarter. North Star Asset Management Inc. now owns 100,289 shares of the company's stock valued at $4,506,000 after acquiring an additional 14,450 shares in the last quarter. Finally, Handelsbanken Fonder AB lifted its holdings in shares of Catalent by 237.7% during the 4th quarter. Handelsbanken Fonder AB now owns 42,400 shares of the company's stock valued at $1,905,000 after acquiring an additional 29,844 shares in the last quarter.

Analyst Ratings Changes

Several research firms recently weighed in on CTLT. UBS Group restated a "neutral" rating and set a $63.50 target price (up previously from $58.00) on shares of Catalent in a report on Tuesday, February 6th. StockNews.com started coverage on shares of Catalent in a report on Saturday. They issued a "sell" rating on the stock. Stephens restated an "equal weight" rating and issued a $63.50 target price on shares of Catalent in a research note on Thursday, April 4th. Royal Bank of Canada restated a "sector perform" rating and issued a $63.50 target price on shares of Catalent in a research note on Tuesday, February 20th. Finally, Barclays upped their target price on shares of Catalent from $45.00 to $47.00 and gave the company an "equal weight" rating in a research note on Thursday, January 25th. Two analysts have rated the stock with a sell rating, nine have assigned a hold rating and three have given a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average target price of $52.46.

Catalent Trading Up 0.3 %

Shares of NYSE:CTLT traded up $0.15 during mid-day trading on Wednesday, hitting $56.00. The stock had a trading volume of 1,636,783 shares, compared to its average volume of 2,510,684. The company has a debt-to-equity ratio of 1.34, a quick ratio of 1.73 and a current ratio of 2.48. The company has a market cap of $10.13 billion, a PE ratio of -8.21, a P/E/G ratio of 6.07 and a beta of 1.20. Catalent, Inc. has a 12-month low of $31.45 and a 12-month high of $60.20. The company's 50 day moving average is $56.61 and its 200-day moving average is $48.85.

Catalent (NYSE:CTLT - Get Free Report) last announced its quarterly earnings results on Friday, February 9th. The company reported ($0.24) EPS for the quarter, missing the consensus estimate of ($0.02) by ($0.22). Catalent had a negative return on equity of 2.43% and a negative net margin of 29.91%. The business had revenue of $1.03 billion for the quarter, compared to analyst estimates of $1.01 billion. During the same quarter last year, the company earned $0.62 EPS. The business's revenue for the quarter was down 10.2% compared to the same quarter last year. On average, sell-side analysts predict that Catalent, Inc. will post 0.28 EPS for the current year.

About Catalent

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.